Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Imagin Medical Inc C.IME

Alternate Symbol(s):  IMEXF

Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.


CSE:IME - Post by User

Bullboard Posts
Comment by TrueNorth911on Aug 28, 2019 5:58pm
91 Views
Post# 30076781

RE:RE:RE:News

RE:RE:RE:NewsHad you read the Clinicaltrials.gov site properly you would have understood the protocol clearly states, "if intense visualization is observed at 10 minutes..."   Now please refer to the press release issued by the company in July of 2018 stating it was recognized at 15 minutes. https://imaginmedical.com/wp-content/uploads/2018/07/Press-Release-7-17-17-Research-Study-Progress.pdf  This is significant since the drug typically takes 60 minutes to express. 
 
Furthermore, a trial must remain open for 1 year which had you actually read the document you would have seen the trial date started Nov 2017 and ended on July 2018. Results first posted for the 2017 trial were on August 19, 2019. Last updated on August 2019. You cannot post results until the official end of a trial. There was no recent trial as you suggest and you look like a fool trying to spread false and misleading statements. 
 
In short the 2017 trial allowed the company to see Dr. Messing's original prototype was workable and as a result, today the company has best-in-breed technology on the cusp of commercialization.
 
No recent trials.  The 2017 trial he is referencing was the thesis for moving forward.

End of subject. 
 
 

Bullboard Posts